Tissue Occluding Agent Comprising an Ieikieikieiki Peptide
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/JP2009/067367, filed Oct 6, 2009. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,801,281 | Tissue Occluding Agent Comprising an Ieikieikieiki Peptide In force · High confidence | 3-D Matrix, Ltd. | In force | High confidence | ||
| US 10,576,123 | Tissue Occluding Agent Comprising an Ieikieikieiki Peptide In force · High confidence | 3-D Matrix, Ltd. | In force | High confidence | ||
| US 10,596,225 | Tissue Occluding Agent Comprising An IEIKIEIKIEIKI Peptide In force · High confidence | 3-D Matrix, Ltd. | In force | High confidence | ||
| Application 16/743,682 | Tissue occluding agent comprising an IEIKIEIKIEIKI peptide Abandoned Abandoned Jan 18, 2022 | 3-D Matrix, Ltd. | Abandoned | Abandoned Jan 18, 2022 | ||
| Application 18/367,908 | Tissue Occluding Agent Comprising an Ieikieikieiki Peptide Pending Not granted | 3-D Matrix, Ltd. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by 3-D Matrix, Ltd..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.